3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
7
Lymphoid
7
Other hematologic neoplasm
5
Thoracic
4
Genitourinary
4
Gynecologic
3
Breast
3
Myeloid
2
Head & Neck
2
Sarcoma
1
Other solid neoplasm
1
Other neoplasm
1
Gastrointestinal
1
Dermatologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Oxaliplatin
297
Fluorouracil
272
Bevacizumab
235
Gemcitabine
234
Leucovorin
212
Capecitabine
204
pembrolizumab
200
Nivolumab
157
Irinotecan
156
Cisplatin
148
Specimen Handling
143
Magnetic Resonance Spectroscopy
130
130-nm albumin-bound paclitaxel
115
Paclitaxel
109
durvalumab
104
Cetuximab
102
Radiotherapy
96
atezolizumab
92
Biopsy
92
Drug Therapy
91
Albumin-Bound Paclitaxel
78
tislelizumab
77
Taxes
73
Folfox protocol
68
lenvatinib
67
Carboplatin
65
regorafenib
60
Blood Specimen Collection
60
trifluridine tipiracil drug combination
52
Ipilimumab
52
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acetaminophen
×
Gastrointestinal
×
1 year
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled